2022
No evidence of fetal defects or anti-syncytin-1 antibody induction following COVID-19 mRNA vaccination
Lu-Culligan A, Tabachnikova A, Pérez-Then E, Tokuyama M, Lee HJ, Lucas C, Monteiro V, Miric M, Brache V, Cochon L, Muenker MC, Mohanty S, Huang J, Kang I, Dela Cruz C, Farhadian S, Campbell M, Yildirim I, Shaw AC, Ma S, Vermund SH, Ko AI, Omer SB, Iwasaki A. No evidence of fetal defects or anti-syncytin-1 antibody induction following COVID-19 mRNA vaccination. PLOS Biology 2022, 20: e3001506. PMID: 35609110, PMCID: PMC9129011, DOI: 10.1371/journal.pbio.3001506.Peer-Reviewed Original ResearchConceptsCOVID-19 mRNA vaccinationMRNA vaccinationEarly pregnancyFetal sizeCoronavirus disease 2019 (COVID-19) mRNA vaccinationSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Respiratory syndrome coronavirus 2Maternal antibody statusAdverse neonatal outcomesSyndrome coronavirus 2Birth defectsPolyinosinic-polycytidylic acidCrown-rump lengthGross birth defectsUnvaccinated adultsMaternal illnessNeonatal outcomesVaccinated adultsAntibody statusTLR3 agonistEarly immunizationMurine pregnancyAntibody inductionCoronavirus 2
2014
Assessment of High-Risk Human Papillomavirus Infections Using Clinician- and Self-Collected Cervical Sampling Methods in Rural Women from Far Western Nepal
Johnson DC, Bhatta MP, Smith JS, Kempf MC, Broker TR, Vermund SH, Chamot E, Aryal S, Lhaki P, Shrestha S. Assessment of High-Risk Human Papillomavirus Infections Using Clinician- and Self-Collected Cervical Sampling Methods in Rural Women from Far Western Nepal. PLOS ONE 2014, 9: e101255. PMID: 24978811, PMCID: PMC4076302, DOI: 10.1371/journal.pone.0101255.Peer-Reviewed Original ResearchConceptsHigh-grade squamous intraepithelial lesionsRural Nepali womenHR-HPVSquamous cell carcinomaHuman papillomavirusHigh-risk human papillomavirus infectionHigh cervical cancer ratesOverall HR-HPV prevalenceSelf-collected cervical samplesHigh-risk HPV typesGrade squamous intraepithelial lesionNepali womenClinician-collected samplesHR-HPV mRNAHR-HPV prevalenceSelf-collected testsCervical cancer ratesHuman papillomavirus infectionSelf-collected samplesSquamous intraepithelial lesionsAuxiliary nurse midwivesPre-cancer lesionsCervico-vaginal specimensSelf-collection methodType-specific distribution
2001
Development and Characterization of a Molecular Viability Assay for Pneumocystis carinii f sp hominis
Maher N, Vermund S, Welsh D, Dillon H, Awooda A, Unnasch T. Development and Characterization of a Molecular Viability Assay for Pneumocystis carinii f sp hominis. The Journal Of Infectious Diseases 2001, 183: 1825-1827. PMID: 11372040, DOI: 10.1086/320738.Peer-Reviewed Original ResearchConceptsPneumocystis carinii pneumoniaHuman immunodeficiency virus-infected personsP. cariniiCommon opportunistic infectionVirus-infected personsCarinii pneumoniaOpportunistic infectionsPerson transmissionHuman P. cariniiClinical specimensTransmission dynamicsCariniiInfectionViability assaysMolecular viabilityImportance of personPneumoniaReliable methodEpidemiologyPersons
2000
Development and Evaluation of a Molecular Viability Assay for Pneumocystis carinii
Maher N, Vermund S, Lasbury M, Lee C, Bartlett M, Unnasch T. Development and Evaluation of a Molecular Viability Assay for Pneumocystis carinii. Journal Of Clinical Microbiology 2000, 38: 1947-1952. PMID: 10790126, PMCID: PMC86630, DOI: 10.1128/jcm.38.5.1947-1952.2000.Peer-Reviewed Original ResearchConceptsPneumocystis carinii pneumoniaRespiratory specimensP. cariniiViable trophozoitesPatient respiratory specimensP. carinii DNAOpportunistic illnessesViability assaysCarinii pneumoniaPCP patientsShock protein 70 familyReverse transcription-PCRHeat shock protein 70 familyPneumocystis cariniiNoninvasive techniqueCarinii DNACariniiTranscription-PCREthidium bromide stainingOptimal assay conditionsTrophozoitesBromide stainingAssaysMolecular viabilitySpecific primers